(Reuters) – Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy kills any cancer cells that may be left in the…
Source:Seattle Genetics and Takeda’s cancer drug meets main trial goal
Monday, September 29, 2014
Seattle Genetics and Takeda's cancer drug meets main trial goal
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment